filings.toolsItem 1A. Risk Factors
3K characters. Original on sec.gov · Markdown
Item 1A. Risk Factors
In addition to the other information set forth in this report, consideration should be given to the factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024. If any of those factors were to occur, they could materially adversely affect our business, financial condition or future results, and could cause actual results to differ materially from those expressed in forward-looking statements in this report. We have not had material changes with respect to the risk factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2024.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
The following table presents the amount of our common share purchase activity for the periods indicated.
| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | Maximum dollar | |
| | | | | | | | Total number of | | value of shares | |
| | | | | | | | shares purchased | | that may yet be | |
| | | Total number of | | Average | | as part of publicly | | purchased under | ||
| | | shares | | price paid | | announced | | the programs (in | ||
| Period | purchased (1) | per share | programs | millions) (2) | ||||||
| January 1, 2025 — January 31, 2025 | 883,214 | | $ | 80.07 | | 883,214 | | $ | 715.5 | |
| February 1, 2025 — February 28, 2025 | 778,084 | | $ | 83.13 | | 664,501 | | $ | 2,160.5 | |
| March 1, 2025 — March 31, 2025 | 1,227,398 | | $ | 85.41 | | 888,509 | | $ | 2,085.8 | |
| April 1, 2025 — April 30, 2025 | | 1,120,281 | | $ | 74.20 | | 1,117,719 | | $ | 2,002.9 |
| May 1, 2025 — May 31, 2025 | | 821,183 | | $ | 77.83 | | 819,237 | | $ | 1,939.1 |
| June 1, 2025 — June 30, 2025 | | 45,668 | | $ | 85.90 | | 42,558 | | $ | 1,935.4 |
| Total | 4,875,828 | | | | | 4,415,738 | | |
| (1) | Includes the number of shares of common stock utilized to execute certain stock incentive awards and shares purchased as part of publicly announced programs. |
|---|
| (2) | In February 2024, our Board authorized a share repurchase program of up to $1.5 billion of our outstanding common stock, which has no expiration date. In February 2025, our Board authorized a share repurchase program of up to $1.5 billion of our outstanding common stock, which has no expiration date. |
|---|
Previous: Item 4. Controls and Procedures · Next: Item 5. Other Information